Fact-checked by Grok 2 weeks ago

B-cell receptor

The B-cell receptor (BCR) is a transmembrane protein complex on the surface of mature B lymphocytes that specifically recognizes and binds antigens, thereby initiating immune responses central to humoral immunity. Composed of a membrane-bound immunoglobulin (mIg) molecule—typically IgM or IgD in naive B cells—paired with the invariant signaling heterodimer CD79a (Ig-α) and CD79b (Ig-β), the BCR enables antigen detection and transduces signals that drive B-cell activation, proliferation, and differentiation into antibody-secreting plasma cells or memory B cells.^[1]^[2] Structurally, the BCR forms a hexameric complex consisting of two identical heavy chains and two identical light chains that constitute the variable antigen-binding Fab regions, along with the Fc region anchored in the plasma membrane and associated with the CD79a/CD79b chains, which contain immunoreceptor tyrosine-based activation motifs (ITAMs) essential for signal propagation. The heavy and light chains are generated through V(D)J recombination, conferring immense diversity to allow recognition of a vast array of antigens without prior exposure. Upon binding soluble or membrane-bound antigens, the BCR clusters, leading to phosphorylation of ITAMs by Src-family kinases such as Lyn, which recruits and activates the tyrosine kinase Syk to amplify the signal.^[1]^[2]^[3] BCR signaling diverges into three major pathways that orchestrate B-cell fate: the PLC-γ2 pathway, which mobilizes calcium and activates NFAT and NF-κB transcription factors to promote survival and differentiation; the PI3K pathway, involving Akt activation to inhibit pro-apoptotic factors and support metabolic reprogramming; and the MAPK/ERK pathway, which induces proliferation via c-Myc expression. These pathways are tightly regulated by positive co-receptors like CD19 and negative feedback molecules such as SHIP-1 and CD22 to prevent aberrant activation. Beyond activation, the BCR plays a pivotal role in B-cell development by providing tonic signals for survival in the bone marrow and periphery, enforcing checkpoints like pre-BCR function to select cells with productive rearrangements, and facilitating processes such as class-switch recombination and affinity maturation in germinal centers. Dysregulated BCR signaling underlies numerous B-cell malignancies, including chronic lymphocytic leukemia, highlighting its therapeutic targeting potential.^[3]^[4]^[5]

Molecular Structure and Composition

Immunoglobulin Domains and Chains

The B-cell receptor (BCR) is a membrane-bound form of immunoglobulin (Ig), consisting of two identical heavy chains and two identical light chains, which together form the core antigen-recognition unit on the B-cell surface.^[6] The heavy chains can belong to one of five isotypes—μ, δ, γ, α, or ε—while the light chains are either κ or λ, with the specific combination determining the BCR's class and function.^[6] These chains are polypeptides, with heavy chains approximately 50 kDa and light chains about 25 kDa, assembled into a Y-shaped structure that enables antigen binding.^[6] The antigen-binding fragment (Fab) region of the BCR comprises the variable (V) domains from both heavy (V_H) and light (V_L) chains, which confer specificity to antigen recognition, paired with constant (C) domains (C_H1 and C_L) that provide structural stability.^[6] Each V domain features hypervariable complementarity-determining regions (CDRs) that form the antigen-binding site, while the C domains in the Fab maintain the overall architecture through non-covalent interactions and disulfide bonds.^[7] In contrast, the crystallizable fragment (Fc) region, formed by the remaining constant domains of the heavy chains (C_H2, C_H3 for most isotypes, or additional C_H4 for μ and ε), includes a transmembrane domain and a short cytoplasmic tail essential for anchoring the BCR to the plasma membrane.^[6] Key structural features stabilize the BCR's modular architecture, including interchain disulfide bonds that link the heavy chains to each other and to the light chains, primarily in the hinge region between Fab and Fc, allowing flexibility for antigen engagement.^[6] Glycosylation sites, particularly on the C_H2 domains in the Fc region, contribute to proper folding, stability, and potential interactions with other molecules.^[7] The hinge region itself provides conformational flexibility, enabling the Fab arms to move independently during antigen binding.^[6] The immunoglobulin fold in the V domains represents a highly conserved structural motif across the immunoglobulin superfamily, characterized by two antiparallel β-sheets stabilized by a disulfide bond, which has evolved from simple cell adhesion roles in early vertebrates to sophisticated antigen recognition in jawed vertebrates.^[8] This conservation underscores the domain's fundamental role in adaptive immunity, with sequence and structural similarities observed from fish to mammals.^[8]

Associated Signaling Molecules (CD79)

The B-cell receptor (BCR) complex includes the heterodimeric signaling subunit composed of CD79a (also known as Ig-α) and CD79b (Ig-β), which are non-covalently associated with the membrane-bound immunoglobulin (mIg) molecule.^[9] CD79a and CD79b form a disulfide-linked heterodimer, each containing a single immunoreceptor tyrosine-based activation motif (ITAM) in their cytoplasmic tails that facilitates signal transduction upon antigen binding.^[10]^[11] The extracellular regions of CD79a and CD79b each feature a single immunoglobulin-like domain that interacts with the Fc portion of the mIg, while their transmembrane domains mediate the assembly of the BCR complex, and their short cytoplasmic tails—61 amino acids for CD79a and 47 amino acids for CD79b—house the ITAM sequences essential for phosphorylation-based signaling initiation.^[12]^[13] In the BCR complex, the stoichiometry is 1:1, with one mIg molecule paired to a single CD79a/CD79b heterodimer, ensuring coordinated antigen recognition and signal propagation.^[14] This association is critical for the stability and surface expression of the BCR, as CD79a and CD79b prevent the retention of unassembled mIg in the endoplasmic reticulum (ER), thereby promoting efficient trafficking to the plasma membrane.^[15] Without functional CD79 heterodimers, surface BCR levels are markedly reduced, underscoring their role in maintaining B-cell responsiveness.^[16] The genes encoding these proteins are located at distinct chromosomal loci in humans: CD79A on chromosome 19q13.2 and CD79B on chromosome 17q23.^[17]^[18] Upon BCR engagement, tyrosine phosphorylation of the ITAMs in CD79a and CD79b represents the initial step in proximal signaling.^[11]

Biosynthesis and Assembly

V(D)J Recombination Process

V(D)J recombination is a site-specific somatic recombination process that assembles the variable regions of immunoglobulin genes in developing B cells, generating a diverse repertoire of B-cell receptors (BCRs) capable of recognizing a vast array of antigens.00675-X) This process is mediated by the V(D)J recombinase system, which includes the lymphocyte-specific enzymes recombination-activating gene 1 (RAG1) and RAG2 that initiate DNA cleavage at recombination signal sequences (RSSs) flanking the variable (V), diversity (D), and joining (J) gene segments.^[19] Following cleavage, the nonhomologous end-joining (NHEJ) DNA repair pathway processes and ligates the gene segments, while terminal deoxynucleotidyl transferase (TdT) adds nontemplated (N) nucleotides at the junctions to further enhance diversity.^[20] The discovery of this mechanism stemmed from Susumu Tonegawa's 1976 experiments demonstrating somatic rearrangement of immunoglobulin genes, for which he received the Nobel Prize in Physiology or Medicine in 1987.^[21] In humans, the immunoglobulin heavy chain locus (IGH) is located on chromosome 14q32.33 and consists of approximately 50 functional V segments, 25 D segments, and 6 J segments, organized in clusters upstream of constant region genes.^[22] The kappa light chain locus (IGK) resides on chromosome 2p11.2 with about 40 functional V segments and 5 J segments, while the lambda light chain locus (IGL) is on chromosome 22q11.2, featuring around 30 V segments and 4-5 J segments.^[23] Each V, D, and J segment is flanked by conserved RSSs, which consist of a heptamer, a spacer of 12 or 23 base pairs, and a nonamer; efficient recombination requires the 12/23 rule, where a 12-spacer RSS pairs only with a 23-spacer RSS.00675-X) The recombination process begins in pro-B cells in the bone marrow with D-to-J joining on the heavy chain locus, where RAG1/RAG2 recognize RSSs flanking a D segment and an adjacent J segment, introducing double-strand breaks to form coding ends (hairpin-sealed) and blunt signal ends.^[24] The NHEJ machinery, including Ku70/Ku80, DNA-PKcs, Artemis, XRCC4, and DNA ligase IV, then opens the hairpins, processes the ends (often adding or deleting nucleotides), and ligates the D and J segments to form a DJ intermediate; this step typically occurs on both IGH alleles.^[20] Subsequently, V-to-DJ joining assembles the complete heavy chain variable region exon by a similar mechanism, pairing a V segment RSS (12-spacer) with the DJ RSS (23-spacer).^[19] For light chains, which lack D segments, recombination proceeds directly from V-to-J joining, first attempting the kappa locus and, if unsuccessful, the lambda locus.00675-X) Signal ends are typically joined to form noncoding signal joints, which are excised as circular DNA, while coding joints form the functional variable region.^[24] During coding joint formation, TdT, a template-independent DNA polymerase expressed in early lymphocytes, adds random N-nucleotides (1-20 bases) primarily at the V-D and D-J junctions of the heavy chain and occasionally at V-J junctions of light chains, significantly contributing to junctional diversity.^[25] TdT activity requires interaction with NHEJ factors like Ku80 for efficient access to coding ends, and its expression peaks during pro-B and pre-B stages before declining in mature B cells.^[26] Exonucleases may also trim nucleotides from segment ends, further varying the junctions.^[20] Allelic exclusion ensures that each B cell expresses a single BCR specificity by enforcing monoallelic expression of productive immunoglobulin alleles.^[27] After a productive VDJ rearrangement on one heavy chain allele yields a functional μ heavy chain, it signals through a pre-BCR to inhibit further heavy chain recombination and promote light chain rearrangement; a similar feedback occurs for light chains, where a productive rearrangement suppresses the other allele.00802-5) This stochastic yet regulated process ensures monospecificity, with allelic inclusion observed in ≤1% of peripheral B cells.^[27] If the first attempt is nonproductive (out-of-frame or stop codon), recombination proceeds on the second allele.^[28]

Post-Translational Modifications and Surface Expression

Following V(D)J recombination, which generates the variable regions of immunoglobulin heavy and light chains, the biosynthesis of the B-cell receptor (BCR) proceeds through intricate post-translational modifications in the endoplasmic reticulum (ER) to ensure proper folding and assembly. The ER chaperone BiP (also known as GRP78) plays a central role in this process by binding to the CH1 domain of newly synthesized immunoglobulin heavy chains, stabilizing their partially folded state and preventing premature secretion of incomplete monomers. This interaction inhibits the association of heavy chains with light chains until the latter are fully folded, thereby enforcing sequential assembly and maintaining the fidelity of BCR formation.^[29] N-linked glycosylation further contributes to BCR maturation by adding oligosaccharide chains that enhance protein stability and facilitate quality control. In immunoglobulin heavy chains, such as the μ chain of IgM (the predominant BCR isotype), N-linked glycans are attached at asparagine residues, including N46 in the CH1 domain and N209 in the CH2 domain; these modifications are essential for proper folding and ER retention of misfolded or unassembled chains. The glycans on the CH1 domain, in particular, are required for efficient assembly with light chains and CD79 heterodimers, acting as checkpoints to prevent trafficking of defective complexes to the Golgi apparatus.^[30] Assembly of the BCR complex requires the association of the membrane-bound immunoglobulin with the CD79α (Igα) and CD79β (Igβ) heterodimer, which masks ER retention signals and enables exit from the ER for subsequent Golgi trafficking and maturation. Without CD79 association, unassembled immunoglobulins are retained in the ER, underscoring the checkpoint role of this interaction in ensuring only complete BCRs reach the cell surface. Mature B cells express approximately 10^5 BCR complexes per cell, which are dynamically clustered within lipid rafts—cholesterol- and sphingolipid-enriched membrane microdomains that facilitate coordinated localization and readiness for antigen engagement.^[15]^[31]^[32] Failures in these quality control mechanisms, such as incomplete assembly or chaperone dissociation errors, trigger ER stress responses or degradation pathways. Unassembled heavy chains are targeted for proteasomal degradation via the ER-associated degradation (ERAD) pathway, mediated by the E3 ubiquitin ligase Hrd1 and the adaptor Sel1L in a BiP-dependent manner, thereby preventing accumulation of toxic aggregates and maintaining ER homeostasis during high-rate immunoglobulin production in B cells.31035-X)

Antigen Recognition and Binding

Binding Affinity and Specificity

The B-cell receptor (BCR) recognizes antigens through precise interactions between its paratope—the antigen-binding site formed by six hypervariable complementarity-determining regions (CDRs) in the immunoglobulin variable domain—and the corresponding epitope on the antigen. These interactions are governed by non-covalent forces, including hydrogen bonds, van der Waals interactions, and electrostatic attractions, which ensure specificity by complementary shape and chemical properties at the interface.^[33]^[34] Naive BCRs, derived from germline sequences, typically display low intrinsic affinity, with dissociation constants (K_d) around 10⁻⁶ M, facilitating broad immune surveillance by allowing detection of diverse antigens at physiological concentrations without premature activation. This modest affinity contrasts with higher values achieved later in responses and supports initial screening of both self and foreign molecules.^[35]^[36] A key feature of germline BCRs is their polyreactivity, enabling low-affinity binding to multiple unrelated antigens, including self-components like DNA or lipids and non-self pathogens; this inherent promiscuity aids in self/non-self discrimination by tolerating weak autoreactivity while prioritizing foreign threats for further selection.^[37]01202-0) Antigen engagement induces conformational changes in the BCR, such as increased separation between the N-terminus and constant domains in the extracellular region of IgM-BCRs, alongside flexibility in the Fab fragment's "elbow" region that adjusts the variable domains' orientation to optimize binding.^[38]^[39] Binding affinity and specificity are quantitatively assessed using surface plasmon resonance (SPR), a label-free optical technique that measures real-time kinetics of association and dissociation to derive K_d values and confirm epitope-paratope complementarity.^[33]^[40]

Role of Somatic Hypermutation

Somatic hypermutation (SHM) plays a crucial role in affinity maturation by introducing point mutations into the variable (V) regions of immunoglobulin genes in activated B cells within germinal centers, thereby enhancing the binding affinity and specificity of the B-cell receptor (BCR) for antigens. This process builds upon the initial diversity generated by V(D)J recombination, allowing for the iterative refinement of BCRs after antigen encounter.^[41] In germinal centers, B cells proliferate rapidly and undergo SHM at a mutation rate of approximately $10^{-3} per base pair per generation, which is about a million times higher than the spontaneous somatic mutation rate, primarily targeting the V regions of rearranged immunoglobulin genes.^[41]^[42] The enzyme activation-induced cytidine deaminase (AID), discovered as essential for both SHM and class-switch recombination, initiates the process by deaminating deoxycytidine residues to deoxyuridine in single-stranded DNA exposed during transcription of immunoglobulin loci in germinal center B cells.00078-7) AID activity is tightly regulated and confined to these activated B cells, where it preferentially targets hotspot motifs such as WRCH (A/T-G-C/T-[A/T]) on the non-template strand and DGYW ( [A/T]-G-[A/T]/[T/A]-C ) on the template strand, leading to elevated mutation frequencies at these sequences—accounting for roughly half of all observed mutations.^[43] Following deamination, the resulting U:G mismatches are processed by error-prone DNA repair pathways, including base excision repair and mismatch repair, which introduce transitions and transversions at both C/G and A/T bases, generating a diverse array of mutations that can improve or impair BCR affinity.^[42] The mutated BCRs are then subjected to selection in the germinal center light zone, where B cells compete for limited antigen displayed on follicular dendritic cells; clones expressing higher-affinity BCRs receive survival signals from T follicular helper cells, proliferate, and re-enter the dark zone for further rounds of mutation and proliferation, culminating in the generation of high-affinity plasma cells and memory B cells.^[44] This Darwinian selection process ensures that only beneficial mutations are retained, dramatically increasing average BCR affinity by 100- to 1000-fold over the course of the immune response. Although AID mediates both SHM and class-switch recombination (CSR), the two processes diverge downstream: SHM favors point mutations via replication across uracils or error-prone polymerases, whereas CSR involves double-strand breaks and non-homologous end joining for isotype switching, despite sharing the initial deamination step.00078-7)^[42]

Signal Transduction Pathways

Initiation and Proximal Signaling

The initiation of B-cell receptor (BCR) signaling occurs upon binding of multivalent antigens to the BCR, which induces cross-linking and clustering of BCR complexes on the B cell surface, thereby facilitating the assembly of signaling molecules.^[45] This clustering is essential for signal propagation, as monovalent ligands fail to trigger robust activation, highlighting the role of BCR oligomerization in overcoming inhibitory constraints.^[46] Proximal signaling commences with the Src-family kinase Lyn, which is non-covalently associated with the BCR, phosphorylating the immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic tails of CD79a and CD79b, the invariant signaling subunits of the BCR.^[47] Each ITAM contains paired tyrosine residues within YxxL/I motifs; Lyn preferentially phosphorylates the first tyrosine, while subsequent phosphorylation of the second tyrosine is mediated by recruited kinases, enabling high-affinity binding.^[48] The doubly phosphorylated ITAMs then recruit the tyrosine kinase Syk via its tandem Src homology 2 (SH2) domains, forming a signalosome that amplifies the initial signal through Syk autophosphorylation and activation of downstream adaptors.^[47] A key early event in proximal signaling is the activation of phospholipase Cγ2 (PLCγ2) by Syk-mediated phosphorylation, which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to produce inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).^[49] IP3 binds to IP3 receptors (IP3R) on the endoplasmic reticulum, triggering rapid calcium influx into the cytosol, which serves as a critical second messenger that activates calcineurin phosphatase. Calcineurin dephosphorylates nuclear factor of activated T cells (NFAT), promoting its nuclear translocation and activation of transcription factors essential for B cell survival and differentiation.^[3] To prevent excessive activation, proximal BCR signaling is tightly regulated by inhibitory mechanisms, notably involving CD22, a sialic acid-binding inhibitory coreceptor. Upon BCR cross-linking, Lyn phosphorylates the ITIM motifs in CD22's cytoplasmic tail, recruiting the protein tyrosine phosphatase SHP-1, which dephosphorylates key substrates such as Syk, Lyn, and adaptor proteins like BLNK, thereby attenuating signal strength and setting the activation threshold.^[50] SHIP-1 also contributes to negative regulation by being recruited to phosphorylated ITAMs or adaptors, where it dephosphorylates PIP3 to limit PI3K pathway activation. This CD22-SHP-1 feedback loop is crucial for modulating B cell sensitivity to antigens, as evidenced by hyperresponsive signaling in CD22-deficient models.^[51]^[3]

Downstream Effector Pathways

Upon activation of the B-cell receptor (BCR), the PI3K-Akt pathway is recruited to promote B-cell survival and proliferation. BCR engagement leads to the recruitment of phosphatidylinositol 3-kinase (PI3K) via phosphorylated adapter proteins, generating phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which in turn activates Akt kinase.^[52] Activated Akt phosphorylates downstream targets such as FoxO transcription factors, inhibiting their nuclear translocation and thereby suppressing pro-apoptotic gene expression to enhance cell survival. Additionally, Akt signaling integrates with metabolic pathways to support proliferation, as evidenced by its role in transitioning pro-B cells to immature B cells expressing surface IgM.^[53] The MAPK/ERK cascade represents another key downstream effector, driving transcription factor activation essential for B-cell responses. Following proximal BCR signals, Ras activation initiates the Raf-MEK-ERK kinase cascade, culminating in ERK1/2 phosphorylation within minutes.^[3] Phosphorylated ERK translocates to the nucleus, where it phosphorylates transcription factors like Elk-1 and components of AP-1 (e.g., c-Fos and c-Jun), promoting the expression of genes involved in cell cycle progression and differentiation.^[54] This pathway is critical for sustaining BCR-induced responses, as ERK activity is required for B-cell proliferation and survival in response to antigen stimulation.^[55] The NF-κB pathway is activated through the CARD11-BCL10-MALT1 (CBM) signalosome complex, facilitating anti-apoptotic effects and cytokine production. BCR crosslinking induces PKCβ-mediated phosphorylation of CARD11, which oligomerizes and recruits BCL10 and MALT1 to form the CBM complex, leading to IKK activation and NF-κB nuclear translocation.^[56] This results in the transcription of anti-apoptotic genes like Bcl-2 and pro-inflammatory cytokines such as IL-6, supporting B-cell expansion and immune modulation.^[57] The pathway preferentially activates the c-Rel subunit of NF-κB in B cells, underscoring its specificity in humoral immunity.^[58] Integration with co-receptors like CD19 amplifies these downstream pathways. CD19, a BCR-associated co-receptor, becomes tyrosine-phosphorylated upon antigen binding, recruiting PI3K to sustain PIP3 production and enhance Akt activation beyond initial BCR signals.^[3] This co-stimulation also potentiates NF-κB and MAPK signaling by lowering the activation threshold, ensuring robust B-cell responses to low-affinity antigens.^[59] BCR signaling exhibits distinct temporal dynamics, with rapid phases occurring in seconds to minutes and sustained phases lasting hours. Proximal events, such as ITAM phosphorylation, trigger immediate kinase activations, while downstream effectors like NF-κB and ERK maintain prolonged signaling through feedback loops, enabling commitment to proliferation and differentiation.^[60] This biphasic nature is mapped in spatiotemporal studies, revealing how early PIP3 accumulation fuels sustained pathway crosstalk.^[61]

Physiological Functions

Activation of Humoral Immunity

The B-cell receptor (BCR) plays a pivotal role in activating naive B cells to initiate humoral immunity, particularly in response to T-dependent antigens, which constitute the majority of protein-based pathogens. Upon antigen binding to the BCR on a naive B cell, the antigen is internalized, processed, and presented as peptides on major histocompatibility complex class II (MHC II) molecules. This presentation enables recognition by antigen-specific CD4+ helper T cells, a process known as linked recognition, where both B and T cells must respond to the same antigenic epitope to ensure specificity and prevent autoimmunity.^[62] T cell activation delivers essential co-stimulatory signals, such as CD40 ligand (CD40L) engagement with CD40 on the B cell and cytokine secretion (e.g., IL-4), which together promote B cell proliferation and differentiation into antibody-secreting cells.^[62] This T cell-dependent pathway is crucial for generating robust, long-term humoral responses, as T-independent antigens, while capable of eliciting rapid IgM production, often fail to produce memory or high-affinity antibodies.^[63] The primary humoral response begins with the secretion of IgM antibodies, which provide an early, pentameric form of defense effective at activating complement and agglutinating pathogens. Naive B cells initially express IgM and IgD on their surface, but upon activation, they rapidly differentiate into plasmablasts that secrete IgM within days of antigen encounter.^[64] Following this initial phase, activated B cells undergo class-switch recombination (CSR), a process mediated by activation-induced cytidine deaminase (AID), which deletes the constant region exons encoding IgM (and IgD) and replaces them with those for IgG, IgA, or IgE.^[64] This switching is directed by cytokines from helper T cells—for example, in mice, IFN-γ directs switching to IgG2a while IL-4 promotes IgG1 and IgE; in humans, cytokines like IL-4 drive switching to IgG4 and IgE, with patterns varying by species—and is essential for tailoring the antibody response to the infection site, with IgG dominating systemic defense, IgA mucosal protection, and IgE anti-parasitic roles.^[64] Humoral activation proceeds through two main pathways: extrafollicular and germinal center (GC), balancing speed and affinity. The extrafollicular pathway generates rapid, low-affinity antibodies via short-lived plasmablasts that emerge within 4–6 days post-antigen exposure, providing immediate protection without extensive somatic hypermutation (SHM).^[65] In contrast, the GC pathway, which develops later (peaking around 2 weeks), involves B cells interacting with T follicular helper cells in lymphoid follicles, enabling iterative SHM and affinity-based selection to produce high-affinity, long-lived plasma cells and memory B cells.^[65] While extrafollicular responses suffice for acute threats like certain bacterial infections, GC-dependent responses are vital for durable immunity, as seen in vaccination where both pathways contribute but GCs dominate for affinity maturation.^[65] BCR-mediated activation is governed by a threshold model, where the density of antigen on the pathogen surface and the resulting BCR-antigen avidity determine whether B cells proliferate or become anergic. High-avidity interactions, often from multivalent antigens with sufficient epitope density (e.g., saturating levels above 50 μg/ml for multivalent phage antigens in experimental models), cross-link multiple BCRs to exceed the signaling threshold, triggering full activation, proliferation, and differentiation.^[66] Conversely, low-avidity or low-density antigens fail to surpass this threshold, leading to incomplete signaling and B cell anergy—a state of unresponsiveness that maintains tolerance to self-antigens.^[66] This model ensures that only relevant threats elicit strong humoral responses, with avidity maturation further refining thresholds during GC reactions.^[46] The BCR's role in humoral activation underscores its evolutionary significance in vertebrates, where it emerged as the cornerstone of adaptive immunity in jawed species (gnathostomes), enabling specific antibody production beyond innate defenses. In early vertebrates like cartilaginous fish, BCRs diversified via V(D)J recombination to recognize diverse pathogens, laying the foundation for humoral defense that evolved across teleosts, amphibians, and mammals.^[67] This innovation allowed vertebrates to mount targeted, memory-based responses, distinguishing them from jawless vertebrates reliant on variable lymphocyte receptors, and highlighting the BCR's adaptation for scalable humoral protection.^[67]

Regulation of B Cell Differentiation

B-cell receptor (BCR) signaling plays a pivotal role in central tolerance by negatively selecting self-reactive immature B cells in the bone marrow. Upon recognition of self-antigens, strong BCR engagement triggers apoptosis through pathways involving increased expression of pro-apoptotic proteins like Bim, leading to clonal deletion of autoreactive clones. Alternatively, weaker self-reactivity can induce receptor editing, where the BCR undergoes further V(D)J recombination to replace the self-reactive heavy or light chain, thereby altering antigen specificity and promoting survival of edited cells. These mechanisms ensure that only non-self-reactive B cells mature and exit the bone marrow.^[68]^[69] In the periphery, BCR signaling maintains tolerance in mature B cells by inducing anergy or deletion of autoreactive clones that encounter self-antigens. Chronic low-level BCR stimulation by self-antigens promotes anergy, a state of unresponsiveness characterized by reduced BCR surface expression, impaired signaling, and downregulation of co-stimulatory molecules, preventing activation without leading to cell death. Stronger peripheral self-antigen encounters can escalate to deletion via activation-induced cell death, mediated by inhibitory receptors like FcγRIIB that dampen BCR signals through recruitment of phosphatases such as SHIP-1. This peripheral checkpoint complements central tolerance to curb autoimmunity.^[70]^[71] BCR signaling further regulates B cell differentiation by modulating key transcription factors that direct lineage commitment. Antigen-driven BCR activation upregulates IRF4, which in turn induces BLIMP1 expression, a master regulator that represses genes for proliferation and germinal center (GC) maintenance while promoting plasma cell differentiation and antibody secretion. Conversely, BCR signals via IRF4 and PU.1 pathways activate Bcl-6, which sustains GC B cell identity by inhibiting BLIMP1 and DNA repair inhibitors, enabling somatic hypermutation and class-switch recombination during affinity maturation. The balance between these factors determines whether activated B cells form short-lived plasmablasts or enter GCs for further differentiation.^[72]^[73] Memory B cell generation is influenced by BCR affinity and signaling strength, favoring the survival of long-lived cells with pre-mutated BCRs for rapid secondary responses. Lower-affinity BCR interactions in GCs, combined with limited T follicular helper cell support, promote memory cell fate over plasma cell differentiation, resulting in quiescent cells that retain high-affinity, somatically hypermutated BCRs from prior GC selection. These memory B cells persist in lymphoid tissues and provide broad protection against antigen variants.^[74]^[75] BCR signaling modulates isotype switching by integrating with cytokine signals to direct antibody class changes. For instance, IL-4 synergizes with BCR and CD40 ligation to promote switching to IgE, inducing germline ε transcript expression and activation-induced cytidine deaminase (AID) via STAT6 and non-canonical NF-κB pathways, enhancing type 2 immune responses. However, excessive BCR cross-linking can inhibit IgE switching through PI3K activation, which suppresses AID via AKT-mediated repression of BLIMP1 and FOXO1.^[76]^[77]

Clinical and Pathological Relevance

Involvement in B Cell Malignancies

In B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), chronic B-cell receptor (BCR) signaling promotes tumor cell proliferation and survival through constitutive activation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the BCR complex.^[78] This dysregulated signaling mimics antigen stimulation, leading to persistent downstream pathways that sustain oncogenesis, as observed in activated B-cell-like DLBCL subtypes where BCR components exhibit enhanced clustering and autophosphorylation.^[79] In CLL, similar chronic signaling contributes to the indolent accumulation of malignant B cells by overriding normal apoptotic controls.^[80] Models of BCR activation in the tumor microenvironment include antigen-independent, cell-autonomous mechanisms where BCR self-ligation or intrinsic aggregation drives signaling without external ligands, fostering a supportive niche in lymph nodes that enhances proliferation.^[81] Alternatively, engagement with autoantigens or self-molecules in the microenvironment can perpetuate low-level BCR stimulation, as evidenced in CLL where nurse-like cells provide survival signals amplifying this process.^[82] These models highlight how microenvironmental cues exploit BCR vulnerabilities to maintain malignancy. Therapeutic strategies targeting BCR signaling have focused on proximal inhibitors like ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that blocks ITAM-mediated activation, inducing apoptosis in CLL and DLBCL cells dependent on this pathway.^[83] Clinical trials demonstrate ibrutinib's efficacy in relapsed/refractory cases, with response rates exceeding 60% in CLL by disrupting BCR-driven survival signals.^[84] In CLL, BCR stereotypy—characterized by biased immunoglobulin heavy chain variable gene (IGHV) usage, such as IGHV1-69 in stereotyped subset #6—correlates with aggressive disease and enhanced autonomous signaling due to structural features enabling self-interactions.^[85] This stereotyped repertoire underscores BCR's role in pathogenesis and informs prognostic stratification.^[86] Post-2020 advances include chimeric antigen receptor (CAR) T-cell therapies exploiting BCR expression, such as mutation-specific CAR-T cells targeting stereotyped BCR sequences like IGLV3-21 in CLL, which selectively eliminate malignant cells while sparing normal B cells.^[87] More recently, as of 2025, bispecific antibodies directed against the IGLV3-21 R110 mutation have shown promise in activating T cells and promoting killing of high-risk CLL subsets.^[88] These approaches leverage BCR's tumor-specific features to overcome antigen escape in refractory B-cell malignancies.

Implications in Autoimmune Disorders

Aberrant B-cell receptor (BCR) function contributes to the breakdown of immune tolerance in autoimmune disorders, allowing self-reactive B cells to persist and drive pathology. In systemic lupus erythematosus (SLE), polyreactive BCRs that recognize nuclear antigens often escape central tolerance checkpoints in the bone marrow due to impaired receptor editing, leading to their accumulation in the peripheral repertoire. Similarly, in rheumatoid arthritis (RA), the first tolerance checkpoint fails, with polyreactive new emigrant B cells comprising 18.5%–27.3% in affected patients compared to 7.4%–9.7% in healthy individuals; these cells produce antibodies reactive to self-antigens like immunoglobulins and cyclic citrullinated peptides.^[89] This defective editing permits autoreactive clones to mature, promoting autoantibody production and tissue damage. In Sjögren's syndrome, B-cell hyperactivity arises from enhanced BCR signaling facilitated by B-cell activating factor (BAFF) overexpression, which disrupts peripheral tolerance and expands autoreactive transitional and marginal zone-like B cells. Elevated BAFF levels in serum and salivary glands correlate with anti-SSA/SSB autoantibodies and prolonged BCR association with lipid rafts, sustaining activation signals and ectopic germinal center formation. This leads to aberrant B-cell distribution and survival of self-reactive clones, exacerbating glandular inflammation. Genetic factors, such as high-risk human leukocyte antigen (HLA) class II alleles, bias the BCR repertoire toward anti-insulin specificities in type 1 diabetes, associating with loss of B-cell anergy and increased autoreactivity. Individuals with HLA-DQ8 or HLA-DR4 haplotypes exhibit expanded insulin-binding B cells that fail peripheral tolerance, linking these alleles to disease susceptibility through altered repertoire selection. Epidemiologically, approximately 70%–90% of SLE patients display anti-nucleosome BCR specificities, reflecting high prevalence of nuclear-reactive clones that correlate with disease activity and nephritis.^[90] Therapeutic strategies targeting BCR-expressing B cells, such as rituximab—an anti-CD20 monoclonal antibody—induce depletion via antibody-dependent cytotoxicity and phagocytosis, mitigating autoimmunity in disorders like RA and granulomatosis with polyangiitis. In RA, rituximab reduces clinical symptoms by eliminating circulating memory B cells, though efficacy varies with incomplete depletion; retreatment sustains remission by maintaining low autoreactive BCR levels. These interventions highlight the central role of dysregulated BCRs in autoimmune pathogenesis.^[91]

References

[1]
Antigen receptor structure and signaling pathways - NCBI - NIH
Thus the complete B-cell receptor is thought to be a complex of six chains—two identical light chains, two identical heavy chains, one Igα, and one Igβ (Fig.
[2]
Structural principles of B cell antigen receptor assembly - PMC - NIH
The B cell antigen receptor (BCR) is composed of a membrane-bound class M, D, G, E or A immunoglobulin for antigen recognition and a disulfide-linked Igα (also ...<|control11|><|separator|>
[3]
The regulators of BCR signaling during B cell activation - PMC
Oct 21, 2019 · In this review, we will discuss three major BCR mediated signaling pathways (the PLC-γ2 pathway, PI3K pathway and MAPK pathway) and related regulators.
[4]
The meaning and relevance of B-cell receptor structure and function ...
The B-cell receptor (BCR) is of critical importance for normal B cells and for the majority of B-cell malignancies, especially chronic lymphocytic leukemia (CLL) ...
[5]
Role of B-cell receptors for B-cell development and antigen-induced ...
Apr 6, 2018 · Signals through the B-cell receptor (BCR) guide and are required for B-cell maturation, survival, and fate decision. Here, we review the role of ...
[6]
The structure of a typical antibody molecule - Immunobiology - NCBI
The Fab fragments correspond to the two identical arms of the antibody molecule, which contain the complete light chains paired with the VH and CH1 domains of ...
[7]
Cryo-EM structure of the human IgM B cell receptor - Science
Aug 18, 2022 · Each light chain comprises two Ig modules, Vκ and Cκ, which together with Vμ and Cμ1 assemble into a Fab domain. Within the Fc domain, Cμ2, Cμ3, ...
[8]
Ig-like domains: Evolution from simple interaction molecules to ... - NIH
Both V and C domains have similar structures called the Ig fold, which is formed by antiparallel β-strands arranged into two sheets linked by a disulfide bond ( ...
[9]
B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ ...
Dec 19, 2023 · Igα (CD79a)/Igβ (CD79b) are essential components of BCR that are indispensable for its functionality, signal initiation, and signal transduction.
[10]
p11912 · cd79a_human - UniProt
Heterodimer of alpha and beta chains; disulfide-linked. Part of the B-cell antigen receptor complex where the alpha/beta chain heterodimer is non-covalently ...
[11]
Monophosphorylation of CD79a and CD79b ITAM motifs initiates a ...
Nov 23, 2011 · Chronic BCR signals maintain anergy in part via ITAM monophosphorylation-directed activation of an inhibitory signaling circuit involving SHIP-1 and Dok-1.
[12]
Characterization of interactions within the Igα/Igβ transmembrane ...
Mar 17, 2022 · The B-cell receptor (BCR), a complex comprised of a membrane-associated immunoglobulin and the Igα/β heterodimer, is one of the most ...
[13]
WO2019241685A1 - Cd79a chimeric antigen receptors
Each also contains a highly conserved transmembrane domain and a 61 (CD79A) or 48 (CD79B) amino acid cytoplasmic tail that also exhibits striking amino acid ...
[14]
Cryo-EM structures of two human B cell receptor isotypes - Science
Aug 18, 2022 · The human IgG-BCR complex structure is composed of the heterodimeric Igα/β and mIgG with a 1:1 stoichiometry, consistent with previous studies ( ...
[15]
Mechanism of CD79A and CD79B support for IgM+ B cell fitness ...
The B-cell receptor (BCR) consists of surface-bound immunoglobulin (Ig) and a heterodimeric signaling unit comprised of CD79A and CD79B.
[16]
T cell and B cell antigen receptors share a conserved core ... - PNAS
Nov 21, 2022 · The B cell and T cell antigen receptors (BCR and TCR) share a common architecture in which variable dimeric antigen-binding modules assemble with invariant ...
[17]
973 - Gene ResultCD79A CD79a molecule [ (human)] - NCBI
CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia. Clinicopathological ...Missing: locus chromosome
[18]
974 - Gene ResultCD79B CD79b molecule [ (human)] - NCBI
This gene encodes the Ig-beta protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been ...
[19]
Role of recombination activating genes in the generation of antigen ...
V(D)J recombination is the process by which antibody and T-cell receptor diversity is attained. During this process, antigen receptor gene segments are cleaved ...
[20]
V(D)J Recombination: Recent Insights in Formation of the ... - Frontiers
Apr 28, 2022 · V(D)J recombination is an essential mechanism of the adaptive immune system, producing a diverse set of antigen receptors in developing lymphocytes.
[21]
Evidence for Somatic Rearrangement of Immunoglobulin Genes ...
Evidence for Somatic Rearrangement of Immunoglobulin Genes Coding for Variable and Constant Regions ... Proc Natl Acad Sci U S A. 1976 Oct;73(10):3628-32. doi: ...<|separator|>
[22]
Large-scale analysis of human heavy chain V(D)J recombination ...
In humans, there are approximately 50 known functional V (variable) segments [3-6], 27 known functional D (diversity) segments [3,7,8], and six known functional ...
[23]
V(D)J Recombination: Molecular Basis of Antibody Diversity and Its ...
Jul 9, 2025 · The recombination process is initiated by the recombination-activating gene products RAG1 and RAG2, which recognize recombination signal ...
[24]
V(D)J Recombination: Recent Insights in Formation of the ...
Apr 29, 2022 · V(D)J recombination is an essential mechanism of the adaptive immune system, producing a diverse set of antigen receptors in developing lymphocytes.V(d)j Recombination: Recent... · Introduction · Rag2 Non-Core Domain...
[25]
Mutational analysis of terminal deoxynucleotidyltransferase ...
May 1, 2004 · The addition of nontemplated (N) nucleotides to coding ends in V(D)J recombination is the result of the action of a unique DNA polymerase, TdT.
[26]
Ku80 is required for addition of N nucleotides to V(D)J ... - NIH
The current model is that TdT adds N regions during V(D)J recombination by random collision with the DNA ends, without a dependence on other cellular factors.
[27]
Allelic exclusion of immunoglobulin genes: models and mechanisms
Ig allelic exclusion serves as the genetic basis of monospecificity of B cells, a phenomenon comparable to the monospecificity of olfactory sensory neurons.
[28]
Allelic Exclusion - an overview | ScienceDirect Topics
Although V(D)J recombination can occur at either Ig allele, mature B cells typically express only a single Ig gene product. This phenomenon, known as allelic ...
[29]
BiP and Immunoglobulin Light Chain Cooperate to Control the ...
The data provided here reveal the mechanism by which heavy chains remain continuously associated with BiP until assembly with completely folded LC is achieved.
[30]
N-linked Fc glycosylation is not required for IgG-B-cell receptor ...
Jan 9, 2024 · Here, we show in a germinal center (GC)-derived human B-cell line that ɣHC glycans do not affect membrane expression of IgG-BCRs.
[31]
The dissociation activation model of B cell antigen receptor triggering
Dec 15, 2010 · To detect its cognate antigen, each B lymphocyte contains up to 120 000 B cell antigen receptor (BCR) complexes on its cell surface.
[32]
Lipid rafts and B cell signaling - PMC - NIH
In this review, we discuss the role of lipid rafts in the activation of B cells. Our major focus is on the role of lipid rafts in the signaling by the BCR.
[33]
Defining and studying B cell and T cell receptor interactions - NIH
Structurally, a BCR can be subdivided into a membrane-bound immunoglobulin (mIg) and signaling domains (10) that are responsible for antigen-binding and B cell ...Introduction · 3d Structure Of Bcrs And... · Binding Affinities And...
[34]
Origins of specificity and affinity in antibody–protein interactions
We found that the energetically critical epitope portions are largely composed of backbone atoms, side-chain carbons, and hydrogen bond donors/acceptors.
[35]
The human naive B cell repertoire contains distinct subclasses for a ...
Jul 4, 2018 · Horizontal dotted line at 10−4 is the limit of detection; the line at 10−6 indicates a reference affinity of 1 μM. Expand for more. Among ...
[36]
regulation of B-cell development by BCR saturation and novel ...
B cells recognize and also discriminate antigen within an affinity range of KD=10−6–10−10 M. We extended this range because beyond the kinetic properties ...
[37]
B cells in the balance: Offsetting self-reactivity avoidance ... - Frontiers
Jul 24, 2022 · If a B cell binds to a foreign antigen but possesses low cross-reactivity or polyreactivity to self-antigens it may still be recruited ...
[38]
Conformational change within the extracellular domain of B cell ...
Jul 10, 2019 · Conformational changes occur within extracellular domain of BCR upon antigen engagement, and these conformational changes are related with ...Missing: elbow flexibility
[39]
Elbow flexibility and ligand-induced domain rearrangements in ...
Four 700-ps molecular dynamics simulations were carried out to analyze the structural dynamics of the antigen-binding antibody fragment NC6.8, ...Missing: BCR | Show results with:BCR
[40]
B cell receptors and free antibodies have different antigen-binding ...
When antigens bind to B cell receptors (BCRs), it triggers the antigen-specific activation of B lymphocytes, which then differentiate into antibody-secreting ...
[41]
Models of Somatic Hypermutation Targeting and Substitution Based ...
Nov 14, 2013 · AID initiates SHM by converting cytosines (Cs) to uracils (Us), thus creating U:G mismatches in the Ig V(D)J sequence. If not repaired before ...<|control11|><|separator|>
[42]
AID AND SOMATIC HYPERMUTATION - PMC - NIH
In response to an assault by foreign organisms, peripheral B cells can change their antibody affinity and isotype by somatically mutating their genomic DNA.Missing: seminal | Show results with:seminal
[43]
Preferential targeting of somatic hypermutation to hotspot motifs and ...
About 50% of the mutations were targeted to the underlined C/G bases in the WRCH/DGYW and RCY/RGY hotspot motifs, indicating that they were due to the initial ...
[44]
Regulated somatic hypermutation enhances antibody ... - Nature
Mar 19, 2025 · Here we experimentally examine a theoretical model that explains how affinity maturation could be optimized by varying the rate of somatic hypermutation.Missing: seminal | Show results with:seminal
[45]
It's All About Change: The Antigen-driven Initiation of B-Cell ...
Here we review progress in understanding the initiation of the BCR signaling ... Ultimately, the rapid growth in the BCR clusters resulted in enhanced downstream ...
[46]
Antigen footprint governs activation of the B cell receptor - Nature
Feb 22, 2023 · Antigen binding by B cell receptors (BCR) on cognate B cells elicits a response that eventually leads to production of antibodies.
[47]
Syk and pTyr'd: Signaling through the B cell antigen receptor - PMC
This review discusses our current understanding of how this phosphorylation regulates the activity of Syk and its participation in signaling through the BCR.
[48]
https://doi.org/10.1016/s1097-2765(02)00739-6
[49]
https://doi.org/10.1038/nri801
[50]
CD22: A Regulator of Innate and Adaptive B Cell Responses and ...
... CD22-SHP-1 activation inhibits downstream signaling. The uptake up of ... CD22 is a negative regulator of B-cell receptor signalling. Curr Biol. (1997) ...
[51]
https://doi.org/10.3389/fimmu.2018.02235
[52]
Targeting PI3K/Akt signal transduction for cancer therapy - Nature
Dec 16, 2021 · BCRs and cytoplasmic adapters profoundly affect PI3K/Akt signaling pathway activation, and Akt is not activated when B cells lack BCRs.
[53]
PI3K signaling controls cell fate at many points in B lymphocyte ...
Genetic dissection of the PI3K pathway in mice has indicated that certain B cell functions are regulated by a limited set of PI3K isoforms and downstream ...
[54]
Ras activation of Erk restores impaired tonic BCR signaling and ...
Feb 22, 2010 · It is well known that Erk is a major downstream effector of the BCR signaling pathway. To determine whether Erk mediates tonic BCR signals that ...Missing: seminal | Show results with:seminal
[55]
ERK phosphorylation is RAF independent in naïve and activated B ...
May 11, 2021 · The kinase activity of ERK is necessary at many stages during B cell differentiation. In most cell types, ERK phosphorylation and activation ...Missing: seminal | Show results with:seminal
[56]
Targeting NF-κB pathway for the therapy of diseases - Nature
Sep 21, 2020 · Phosphorylated CARD11 undergoes a conformational change, leading to the recruitment of Bcl10 (B cell lymphoma 10) and MALT1 (mucosa-associated ...
[57]
The CARD11-BCL10-MALT1 (CBM) signalosome complex
Consequently, other CARD proteins replace CARD11 and interact with BCL10 and MALT1 to form a CBM complex in other cells, inducing NF-κB activation in receptor ...
[58]
Antigen Receptor Signaling to NF-κB via CARMA1, BCL10, and ...
MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunit. Nature Immunol 8: 4–991 [DOI] [PubMed] ...
[59]
CD19 differentially regulates BCR signalling through the ... - PubMed
Jun 23, 2014 · We propose that CD19 can modulate BCR signalling in both a positive and negative manner depending on the receptor/ligand interaction in vivo.
[60]
A PIP2-derived amplification loop fuels the sustained initiation of B ...
Next, we examined the temporal dynamics of the spatial distribution of PIP2 and BCR microcluster by time-lapse TIRFM imaging. The results showed that PIP2 was ...
[61]
A Spatiotemporal Map of Co-Receptor Signaling Networks ...
This study provides a comprehensive map of the BCR signaling pathway and a rich resource for uncovering the complex signaling networks that regulate B cell ...
[62]
B-cell activation by armed helper T cells - Immunobiology - NCBI - NIH
T-cell dependent antibody responses require the activation of B cells by helper T cells that respond to the same antigen; this is called linked recognition.
[63]
Review B Cell Responses: Cell Interaction Dynamics and Decisions
Apr 18, 2019 · In this review, we give an overview of how B cells travel throughout the body surveying for antigen, how they respond upon antigen encounter, how they go on to ...
[64]
Immunoglobulin class‐switch recombination: Mechanism, regulation ...
Maturation of the secondary antibody repertoire requires class‐switch recombination (CSR), which switches IgM to other immunoglobulins (Igs), and somatic ...
[65]
Germinal Center and Extrafollicular B Cell Responses in vaccination ...
B cell responses track towards either germinal center or extrafollicular responses. The extrafollicular response is increasingly being appreciated as a dominant ...
[66]
Antigens Varying in Affinity for the B Cell Receptor Induce ...
The B cell receptor (BCR) triggers a variety of biological responses that differ depending upon the properties of the antigen.
[67]
Evolution of B Cell Immunity - PMC - PubMed Central
Here we summarize features of B cells and their predecessors in the different animal phyla, focusing the review on B cells from jawed vertebrates.
[68]
Central B-Cell Tolerance: Where Selection Begins - PMC
Investigators have identified the central tolerance mechanisms that negatively select autoreactive immature B cells and prevent inclusion of their antigen ...
[69]
Mechanisms of central tolerance for B cells - PMC
Tolerance is regulated at the stage of immature B cell development (central tolerance) by clonal deletion, involving apoptosis, and by receptor editing.
[70]
The role of inhibitory signaling in peripheral B cell tolerance - PMC
In this review article, I will focus on B cell-intrinsic mechanisms that prevent the activation of autoreactive B cells in the periphery.
[71]
Self-reactivity on a spectrum: a sliding scale of peripheral B cell ...
In this review, we discuss new insights into mechanisms of peripheral B cell tolerance that restrain mature B cells from mounting inappropriate responses to ...
[72]
Transcription factors regulating B cell fate in the germinal centre - NIH
One of the critical functions of BCL6 appears to be the repression of PC differentiation, in this case mediated by repression of BLIMP1 56 (see below); thus, ...
[73]
https://doi.org/10.1038/msb.2011.25
[74]
B cell memory: from generation to reactivation - Nature
Mar 7, 2024 · ... B cell receptor (BCR) signaling over time determines the fate of GC B cells. Repeated proliferation cycles gradually reduce the capability ...
[75]
Transcriptional regulation of memory B cell differentiation - PMC
Oct 6, 2020 · This Review discusses the signals and transcription factors that regulate the development and function of germinal centre-derived memory B cells.<|separator|>
[76]
Signaling Control of Antibody Isotype Switching - PubMed Central
While the BCR plays a central role in activating B cells and determining the specificity of isotype-switched antibodies, how BCR signaling regulates CSR is ...
[77]
https://doi.org/10.1038/ncomms1769
[78]
B-cell receptor signaling as a driver of lymphoma development and ...
Sep 20, 2013 · In an increasing number of B-cell malignancies, BCR signaling is implicated as a pivotal pathway in tumorigenesis.
[79]
B-cell receptor signalling and its crosstalk with other pathways in ...
Here we describe the current knowledge of the specific aspects of BCR signalling in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, chronic ...
[80]
Antigen-independent, autonomous B cell receptor signaling drives ...
May 6, 2024 · Autonomous BCR signaling represents a novel immunological oncogenic driver mechanism in DLBCL originating from individual BCR sequences.
[81]
Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies
In preclinical studies, ibrutinib potently bound to Btk, inhibited BCR signaling, and decreased tumor cell proliferation and survival in many B-cell malignancy ...
[82]
Targeting Bruton's tyrosine kinase in B cell malignancies - Nature
Mar 24, 2014 · Ibrutinib was also used to show that BTK is involved in oncogenic BCR signalling that controls the survival of a human activated B cell-like ...
[83]
Distinct homotypic B-cell receptor interactions shape the outcome of ...
Jun 9, 2017 · Cell-autonomous B-cell receptor (BcR)-mediated signalling is a hallmark feature of the neoplastic B lymphocytes in chronic lymphocytic leukaemia (CLL).
[84]
https://www.nature.com/articles/nrc3702
[85]
Mutation-specific CAR T cells as precision therapy for IGLV3-21 ...
Feb 2, 2024 · B cell receptors (BCR) of mature lymphoid malignancies are exceptional in that they harbor tumor-specific-stereotyped sequences in the form ...Anti-R110-Mcar Car T Cells... · Healthy Donor Or Cll... · Car T Cell In Vivo Assays<|control11|><|separator|>
[86]
https://www.nature.com/articles/s41375-022-01600-6
[87]
https://www.nature.com/articles/s41467-024-45378-w
[88]
https://haematologica.org/article/view/12266